ReviewIndian journal of dermatology, venereology and leprology
The unprecedented epidemic-like scenario of dermatophytosis in India: III. Antifungal resistance and treatment options.
Review in Indian journal of dermatology, venereology and leprology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Pooled it
- Comparative Efficacy of Terbinafine, Itraconazole, and Griseofulvin in Treatment of Steroid-Modified Tinea.Indian dermatology online journal · 2026Article
- Unraveling CARD9 Mutations in Deep Dermatophytosis: A Genetic Gateway to Fungal Invasion and Immune Dysfunction.Journal of fungi (Basel, Switzerland) · 2026Review
- The emergence of superficial dermatophytosis due toJournal of clinical microbiology · 2026Article
- The Evolving Landscape of Dermatophytosis in the UAE: Trichophyton indotineae and Related Genotypes.Mycoses · 2026Article
- Trichophyton indotineae: Epidemiology, antifungal resistance and antifungal stewardship strategies.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Review
- [Trichophyton mentagrophytes ITS genotype VIII/Trichophyton indotineae in Germany-revisit after 5 years].Dermatologie (Heidelberg, Germany) · 2025Article
- Terbinafine Resistance inAntibiotics (Basel, Switzerland) · 2025Review
- Dermatophyte Treatment Failure: A Rapid Global Response to an Emerging Global Health Issue.Acta dermato-venereologica · 2025Article
- NEXTODERM: Consensus on Dermatophytosis Diagnosis and Management in Nepal.Dermatology research and practice · 2025Review
- Comprehensive Review on Tinea Infection Therapies: Allopathic and Herbal Approaches for Dermatophytosis.Recent advances in anti-infective drug discovery · 2025Review
- Dermatophytosis Caused by Trichophyton indotineae (Trichophyton mentagrophytes ITS Genotype VIII) in Sri Lanka.The American journal of tropical medicine and hygiene · 2024Article
- [Dermatomycoses: topical and systemic antifungal treatment].Dermatologie (Heidelberg, Germany) · 2024Review
- Article
- A Current Diagnostic and Therapeutic Challenge: Tinea Capitis.Journal of clinical medicine · 2024Article
- Antifungal Resistance, Susceptibility Testing and Treatment of Recalcitrant Dermatophytosis Caused by Trichophyton indotineae: A North American Perspective on Management.American journal of clinical dermatology · 2023Review
- Insights into Changing Dermatophyte Spectrum in India Through Analysis of Cumulative 161,245 Cases Between 1939 and 2021.Mycopathologia · 2023Article
- Potential Inhibitory Effect of Miltefosine against Terbinafine-ResistantPathogens (Basel, Switzerland) · 2023Article
- Current Topics in Dermatophyte Classification and Clinical Diagnosis.Pathogens (Basel, Switzerland) · 2022Review
- Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the canonical features of the current outbreak of dermatophytosis in India is its unresponsiveness to treatment in majority of cases. Though there appears to be discordance between in vivo and in vitro resistance, demonstration of in vitro resistance of dermatophytes to antifungals by antifungal susceptibility testing is essential as it may help in appropriate management. The practical problem in the interpretation of antifungal susceptibility testing is the absence of clinical breakpoints and epidemiologic cutoff values. In their absence, evaluation of the upper limit of a minimal inhibitory concentration of wild type isolates may be beneficial for managing dermatophytosis and monitoring the emergence of isolates with reduced susceptibility. In the current scenario, most of the cases are unresponsive to standard dosages and duration of treatment recommended until now. This has resulted in many ex-cathedra modalities of treatment that are being pursued without any evidence. There is an urgent need to carry out methodical research to develop an evidence base to formulate a rational management approach in the current scenario.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.